Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04592445 · ClinicalTrials.gov registry record · NA
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
A NA study of Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Axon Therapies.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT04592445: Recruiting NA study of Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Axon Therapies.
NCT04592445 is a NA study of Heart Failure With Preserved Ejection Fraction (HFPEF) that is actively recruiting participants, run by Axon Therapies. The registered enrollment target is 150 participants, below the 203-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04592445, a NA study of Heart Failure With Preserved Ejection Fraction (HFPEF), is actively recruiting participants, sponsored by Axon Therapies.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.
Primary Outcome
Evaluation of device or procedure-related serious adverse events at 1-month follow-up based on Clinical Events Committee (CEC) assessment
Conditions Studied
Interventions
- DEVICE Sham Control
- DEVICE Greater Splanchnic Nerve Ablation
Study Locations (20)
New York
- Weill Cornell Medicine - New York
- Icahn School of Medicine at Mount Sinai - New York
- Columbia University Medical Center - New York
- Rochester General Hospital - Rochester
Illinois
- Bluhm Cardiovascular Institute of Northwestern University - Chicago
- University of Chicago Medical Center - Chicago
- Prairie Education and Research Cooperative - Springfield
California
- Scripps Health - La Jolla
- University of California, San Francisco - San Francisco
Alabama
- Cardiology PC - Birmingham
Arizona
- Arizona Cardiovascular Research Center - Phoenix
Indiana
- Ascension St. Vincent - Cardiovascular Research Institute - Indianapolis
Louisiana
- Cardiovascular Institute of the South - Houma
Michigan
- Michigan Medicine, University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-12-18 |
| Est. Completion | 2029-08-10 |
| Phase | NA |
What NCT04592445 shows while recruiting
NCT04592445 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 203-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (26% lower).
The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction (HFPEF) appearing as the primary indexed condition, and to 2 interventions - of which Sham Control is the first listed.
NCT04592445 names 20 study sites across 14 states, led by New York, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT04592445 about?
NCT04592445 is a clinical study titled "Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF". The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether th...
What is the current status of trial NCT04592445?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2020-12-18. Estimated completion is 2029-08-10.
What conditions does trial NCT04592445 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction (HFPEF).
What interventions are being tested in trial NCT04592445?
The interventions under investigation include: Sham Control (DEVICE), Greater Splanchnic Nerve Ablation (DEVICE).
Who is sponsoring clinical trial NCT04592445?
This trial is sponsored by Axon Therapies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04592445 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction (HFPEF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04592445's enrollment target sits among peer trials
150 5th of 9 higher than 5 of 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction (HFPEF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ELEVATE-HFpEF Clinical Study
RECRUITING · NA
-
Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study
ACTIVE NOT RECRUITING · NA
-
The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
RECRUITING
-
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 1
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI